Bon Natural Life (BON) Competitors $1.36 -0.02 (-1.45%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsTrends BON vs. BMRA, CDIO, BFRI, HOTH, PRTG, GNPX, ORGS, ENSC, ERNA, and XCURShould you be buying Bon Natural Life stock or one of its competitors? The main competitors of Bon Natural Life include Biomerica (BMRA), Cardio Diagnostics (CDIO), Biofrontera (BFRI), Hoth Therapeutics (HOTH), Portage Biotech (PRTG), Genprex (GNPX), Orgenesis (ORGS), Ensysce Biosciences (ENSC), Eterna Therapeutics (ERNA), and Exicure (XCUR). These companies are all part of the "pharmaceutical products" industry. Bon Natural Life vs. Biomerica Cardio Diagnostics Biofrontera Hoth Therapeutics Portage Biotech Genprex Orgenesis Ensysce Biosciences Eterna Therapeutics Exicure Biomerica (NASDAQ:BMRA) and Bon Natural Life (NYSE:BON) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, community ranking, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability. Does the MarketBeat Community favor BMRA or BON? Biomerica received 137 more outperform votes than Bon Natural Life when rated by MarketBeat users. CompanyUnderperformOutperformBiomericaOutperform Votes13767.82% Underperform Votes6532.18% Bon Natural LifeN/AN/A Do analysts rate BMRA or BON? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomerica 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ABon Natural Life 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Is BMRA or BON more profitable? Bon Natural Life has a net margin of 0.00% compared to Biomerica's net margin of -111.89%. Bon Natural Life's return on equity of 0.00% beat Biomerica's return on equity.Company Net Margins Return on Equity Return on Assets Biomerica-111.89% -84.62% -62.72% Bon Natural Life N/A N/A N/A Does the media prefer BMRA or BON? In the previous week, Biomerica and Biomerica both had 2 articles in the media. Bon Natural Life's average media sentiment score of 0.47 beat Biomerica's score of 0.23 indicating that Bon Natural Life is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomerica 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bon Natural Life 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings and valuation, BMRA or BON? Bon Natural Life has higher revenue and earnings than Biomerica. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiomerica$5.41M1.16-$5.98M-$0.37-1.01Bon Natural Life$29.52M0.05$4.60MN/AN/A Which has more volatility and risk, BMRA or BON? Biomerica has a beta of -1.11, suggesting that its stock price is 211% less volatile than the S&P 500. Comparatively, Bon Natural Life has a beta of -1.23, suggesting that its stock price is 223% less volatile than the S&P 500. Do insiders & institutionals have more ownership in BMRA or BON? 22.3% of Biomerica shares are owned by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are owned by institutional investors. 15.0% of Biomerica shares are owned by insiders. Comparatively, 26.5% of Bon Natural Life shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryBon Natural Life beats Biomerica on 7 of the 11 factors compared between the two stocks. Ad Chaikin AnalyticsSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA). Get Bon Natural Life News Delivered to You Automatically Sign up to receive the latest news and ratings for BON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BON vs. The Competition Export to ExcelMetricBon Natural LifeMedicinals & botanicals IndustryDiscretionary SectorNYSE ExchangeMarket Cap$1.59M$1.32B$8.16B$19.25BDividend YieldN/AN/A2.75%3.54%P/E RatioN/A7.2716.1641.13Price / Sales0.058.1231.3914.78Price / Cash0.2915.7533.6720.83Price / Book0.042.095.435.38Net Income$4.60M-$52.95M$262.99M$985.39M7 Day Performance-6.69%-0.54%-0.09%-0.70%1 Month Performance-26.49%6.49%1.85%-0.97%1 Year Performance-71.67%11.77%59.55%25.06% Bon Natural Life Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BONBon Natural LifeN/A$1.36-1.4%N/A-67.6%$1.59M$29.52M0.00100Gap UpBMRABiomerica0.9097 of 5 stars$0.37flatN/A-61.3%$6.26M$5.41M-1.0160Short Interest ↓News CoverageCDIOCardio Diagnostics3.2883 of 5 stars$0.26-7.1%$2.00+669.2%-17.1%$6.22M$20,000.000.007Gap UpHigh Trading VolumeBFRIBiofrontera2.2395 of 5 stars$1.09-11.4%$7.00+542.2%-76.9%$6.04M$34.07M-0.1870News CoverageGap DownHigh Trading VolumeHOTHHoth Therapeutics3.3034 of 5 stars$0.86+1.2%$3.50+307.0%-27.1%$5.87MN/A-0.534Gap UpPRTGPortage Biotech1.6611 of 5 stars$5.58-1.8%$120.00+2,050.5%-85.4%$5.86MN/A-0.126Positive NewsGap DownGNPXGenprex4.3388 of 5 stars$2.15-4.4%$10.00+365.1%-76.0%$5.82MN/A0.0020Short Interest ↑News CoverageORGSOrgenesis1.8506 of 5 stars$1.20flatN/AN/A$5.76M$530,000.000.00150Positive NewsGap UpENSCEnsysce Biosciences1.0183 of 5 stars$0.65+12.1%N/A-26.4%$5.73M$2.23M-0.2310Gap UpHigh Trading VolumeERNAEterna Therapeutics0.2427 of 5 stars$1.04-4.6%N/A-15.4%$5.63M$70,000.00-0.2410Short Interest ↑News CoverageXCURExicure1.7236 of 5 stars$3.16+4.3%N/A+409.7%$5.47M$28.83M-0.6950 Related Companies and Tools Related Companies Biomerica Competitors Cardio Diagnostics Competitors Biofrontera Competitors Hoth Therapeutics Competitors Portage Biotech Competitors Genprex Competitors Orgenesis Competitors Ensysce Biosciences Competitors Eterna Therapeutics Competitors Exicure Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:BON) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bon Natural Life Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Bon Natural Life With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
